EGFR and neoplasm: For example, the overexpression of the epithelial growth factor receptor (EGFR) can promote the neovascularization of tumor tissue and promote tumor proliferation and migration; however, anti-EGFR monoclonal antibodies have been used clinically for several years to kill tumor cells and delay the malignant progression of tumor patients (Santos et al., 2021).